参考文献

[1] Fire A, Xu S, Montgomerym K, et al. Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans [J]. Nature, 1998, 391(6669): 806-811.

[2] Montgomery MK, Xu S, Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans [J]. Proc Natl Acad Sci USA, 1998, 95(26): 15502-15507.

[3] Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs [J]. Cell, 2006, 126(2): 231-235.

[4] Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs [J]. Nature, 2004, 432(7014): 173-178.

[5] Chen CC, Chang CM, Sun CP, et al. Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus [J]. Gene Ther, 2012, 19(1): 25-33.

[6] Xia H, Mao Q, Eliason SL, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia [J]. Nat Med, 2004, 10(8): 816-820.

[7] Yang WQ, Zhang Y. RNAi-mediated gene silencing in cancer therapy [J]. Expert Opin Biol Ther, 2012, 12(11): 1495-1504.

[8] Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster [J]. Nat Genet, 2006, 38 (9): 1060-1065.

[9] Valastyan S, Reinhardt F, Benaich N, et al. A pleiotropically acting microRNA,miR-31,inhibits breast cancer metastasis [J]. Cell, 2009, 137(6): 1032-1046.

[10] Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis [J]. Nature, 2008, 451 (7175): 147-152.

[11] Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia [J]. N Engl J Med, 2005, 353(17): 1793-1801.

[12] Tomimaru Y, Eguchi H, Nagano H, et al. MicroRNA−21 induces resistance to the anti-tumour effect of interferonalpha/5−fluorouracil in hepatocellular carcinoma cells [J]. Br J Cancer, 2010, 103(10): 1617-1626.

[13] Park JK, Kogure T, Nuovo GJ, et al. miR−221 silencing blocks hepatocellular carcinoma and promotes survival [J]. Cancer Res, 2011, 71 (24): 7608-7616.

[14] Callegari E, Elamin BK, Giannone F, et al. Liver tumorigenicity promoted by microRNA−221 in a mouse transgenic model [J]. Hepatology, 2012, 56(3): 1025-1033.

[15] Liu P, Qi M, Ma C, et al. Let7a inhibits the growth of endometrial carcinoma cells by targeting Aurora-B [J]. FEBS Lett, 2013, 587(16): 2523-2529.

[16] Zhang H, Luo XQ, Feng DD, et al. Upregulation of microRNA−125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia [J]. Mol Cancer, 2011, 10: 108.

[17] Rai D, Kim SW, McKeller MR, et al. Targeting of SMAD5 links microRNA−155 to the TGF-beta pathway and lymphomagenesis [J]. Proc Natl Acad Sci USA, 2010, 107(7): 3111-3116.

[18] Zhang YP, Kong QH, Huang Y, et al. Inhibition of c-FLIP by RNAi Enhances Sensitivity of the Human Osteogenic Sarcoma Cell Line U2OS to TRAIL-Induced Apoptosis [J]. Asian Pac J-Cancer Prev, 2015, 16(6): 2251-2256.

[19] Zhang Y, Chen L, Yang S, Fang D. E2F1: a potential negative regulator of hTERT transcription in normal cells upon activation of oncogenic c-Myc [J]. Med Sci Monit, 2012, 18(1): RA12-15.

[20] Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy [J]. Nature, 2004, 429 (6990): 457-463.

[21] Ferreira AC, Robaina MC, Rezende LM, et al. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101 [J]. Ann Hematol, 2014, 93(6): 983-993.

[22] Ørom UA, Derrien T, Beringer M, et al. Long noncoding RNAs with enhancer-like function in human cells [J]. Cell, 2010, 143(1): 46-58.

[23] Spadaro PA, Flavell CR, Widagdo J, et al. Long noncoding RNA-Directed epigenetic regulation of gene expression is associated with anxiety-like behavior in mice [J]. Biol Psychiatry, 2015, pii: S0006-3223(15)00095-5.

[24] Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects [J]. Int J Biochem Cell Biol, 2013, 45(8): 1895-1910.

[25] Wapinski O, Chang HY. Long noncoding RNAs and human disease [J]. Trends Cell Biol, 2011, 21: 354-361.

[26] Clark MB, Mattick JS. Long noncoding RNAs in cell biology [J]. Semin Cell Dev Biol, 2011, 22(4): 366-376.

[27] Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas [J]. Mol Cancer, 2011, 10: 38.

[28] Isin M, Dalay N. LncRNAs and neoplasia [J]. Clin Chim Acta, 2015, 444: 280-288.

[29] Lai MC, Yang Z, Zhou L, et al. Long non-coding RNA MALAT−1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation [J]. Med Oncol, 2012, 29(3): 1810-1816.

[30] Schmidt LH, Spieker T, Koschmieder S, et al. The long noncoding MALAT−1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth [J]. J Thorac Oncol, 2011, 6(12): 1984-1992.

[31] Tano K, Mizuno R, Okada T, et al. MALAT−1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes [J]. FEBS Lett, 2010, 584(22): 4575-4580.

[32] Ying L, Chen Q, Wang Y, et al. Upregulated MALAT−1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition [J]. Mol Biosyst, 2012, 8(9): 2289-2294.

[33] Kim K, Jutooru I, Chadalapaka G, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer [J]. Oncogene, 2013, 32(13): 1616-1625.

[34] Yang Z, Zhou L, Wu LM, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation [J]. Ann Surg Oncol, 2011, 18(5): 1243-1250.

[35] Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis [J]. Nature, 2010, 464(7291): 1071-1076.

[36] Geng YJ, Xie SL, Li Q, et al. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression [J]. J Int Med Res, 2011, 39(6): 2119-2128.

[37] Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles [J]. Nature, 2010, 464(7291): 1067-1070.

[38] Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement [J]. Cancer Discov, 2013, 3(4): 406-417.

[39] Leenders F, Mopert K, Schmiedeknecht A, et al. PKN3 is required for malignant prostate cell growth downstream of activated PI 3−kinase [J]. EMBO J, 2004, 23(16): 3303-3313.

[40] Strumberg D, Schultheis B, Traugott U, et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors [J]. Int J Clin Pharmacol Ther, 2012, 50 (1): 76-78.

[41] Craig SN, Wyatt MD, McInnes C. Current assessment of polo-like kinases as anti-tumor drug targets [J]. Expert Opin Drug Discov, 2014, 9(7): 773-789.

(收稿日期:2015-05-07)